Clinical Scorecard: Tumor Size as an Indicator of Post-Surgical Speech Difficulties in Pediatric Patients Undergoing Posterior Fossa Tumor Resection: A Prospective Multicenter Analysis

At a Glance

Key Highlights

• CMS affects approximately 30% of pediatric posterior fossa tumor surgery cases, characterized mainly by postoperative speech impairment ranging from reduced speech to mutism.
• Larger posterior fossa tumor volumes, measured by semi-automated 3D segmentation (SmartBrush™), may correlate with increased risk of POSI.
• Tumor location involving brainstem or 4th ventricle is associated with higher risk of POSI compared to tumors in vermis or cerebellar hemispheres.

Guideline-Based Recommendations

Diagnosis

• Preoperative MRI with contrast-enhanced T1 sequences should be used for tumor volume measurement using semi-automated segmentation tools like SmartBrush™.
• Postoperative speech assessment within 1–4 weeks to classify speech status as habitual, reduced, or mutism.

Management

• Surgical planning should consider tumor volume and location to mitigate risk of postoperative speech impairment.
• Risk stratification should incorporate tumor size, pathology (e.g., medulloblastoma), and anatomical involvement (brainstem, 4th ventricle).

Monitoring & Follow-up

• Neurological and speech assessments preoperatively and postoperatively to monitor for CMS symptoms.
• Long-term follow-up for neurocognitive and motor function due to potential persistent deficits.

Risks

• Larger tumor volumes may require more extensive surgical manipulation increasing risk of CMS.
• Tumors infiltrating or compressing brainstem or 4th ventricle carry higher risk of postoperative speech impairment.

Patient & Prescribing Data

Pediatric patients (<18 years) undergoing posterior fossa tumor resection

Accurate preoperative tumor volumetry and location assessment can guide surgical approach to reduce risk of postoperative speech impairment and improve outcomes.

Clinical Best Practices

• Utilize semi-automated 3D segmentation tools (e.g., SmartBrush™) for precise tumor volume measurement preoperatively.
• Classify tumor location into risk categories (brainstem, 4th ventricle, vermis, cerebellar hemisphere) to inform surgical risk.
• Perform standardized speech and neurological assessments pre- and post-surgery to detect and manage CMS early.
• Incorporate tumor pathology and volume data into multidisciplinary surgical planning to optimize patient outcomes.

References

• European study of the cerebellar mutism syndrome in children with brain tumours of the posterior fossa
• SmartBrush™ tool for tumor volumetry in neurosurgery